Zunveyl is a next-generation acetylcholinesterase inhibitor approved in the U.S. for mild-to-moderate Alzheimer's disease.
For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...
Alzheimer’s disease is the most common cause of dementia in older adults. But according to experts, the condition affects men ...
The New Brunswick, N.J., pharmaceutical giant said posdinemab has shown potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid from treated Alzheimer's patients, and in ...
Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...
Researchers have discovered that suppressing a nucleolar complex can reduce Alzheimer’s-related protein toxicity. Scientists ...
An international team of scientists has uncovered new insights into how the previously understudied duplicate X chromosome in ...
A study of human brain organoids suggested a complex relationship between herpes simplex virus 1 infection and tau, ...
POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease ...
Seth Rogen and wife Lauren Miller Rogen open up to PEOPLE about their upcoming documentary, Taking Care, which shares their ...